Techne (TECH) came out with quarterly earnings of $0.49 per share, missing the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -3.92%. A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.46 per share when it actually produced earnings of $0.48, delivering a surprise of 4.35%. Over the ...

MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable August 30, 2024, to all common shareholders of record on August 19, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bio ...

MINNEAPOLIS, July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems. This stateof-the-art instrument enables simultaneous processing of up to 100 samples in a single 3-hour run, allowing scientists to process more samples in a day. Leo also provides 4-times the experimental size of Jess ...

MINNEAPOLIS, July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. BioTechne joined Foresite Capital, and other investors, in this funding round. Founded in 2021 and headquartered in Woburn, Massachusetts, Spear Bio is an innovative leader in the development, and manu ...

Core Viewpoint - Oddity Tech Ltd. and certain executives are facing charges for failing to disclose material information during the Class Period, which is a violation of federal securities laws [1]. Group 1: Legal Proceedings - Investors have until September 17, 2024, to file lead plaintiff applications in a securities class action lawsuit against Oddity, covering purchases made between July 19, 2023, and May 20, 2024 [2]. - The lawsuit is currently pending in the United States District Court for the Eastern District of New York [2]. - The case is identified as Hoare v. Oddity Tech Ltd., et al., 24-cv-05037 [5]. Group 2: Allegations Against Oddity - NINGI Research reported multiple allegations against Oddity, claiming the company misled investors about critical aspects of its business [4]. - Allegations include that Oddity's AI is merely a questionnaire and that its reported "repeat purchase rates" are due to customers unknowingly entering non-cancelable plans [4]. - NINGI also found numerous undisclosed lawsuits against Oddity and its subsidiaries in the US and Israel, often related to unpaid bills and consumer protection law violations [4]. Group 3: Market Reaction - Following the news of the allegations, Oddity's share price dropped by $3.02, or 7.37%, closing at $37.97 per share on May 21, 2024 [7].

NEW ORLEANS, July 23, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. ("Oddity" or the "Company") (NasdaqGM: ODD), if they purchased the Company's securities between July 19, 2023 and May 20, 2024, inclusive (the "Class Period"). This action is pending in the United State ...

Click here to participate in the action. If you purchased or otherwise acquired Oddity Tech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you ...

These are just a few of the metrics contributing to GMAB's Value grade of B and TECH's Value grade of D. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. Value investors also tend to look at a n ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels. Another notable valuation metric for GMAB is its P/B ratio of 3.57. The P/B ...

CETI's focus is to treat and repurpose a substantial amount of the water it receives from oil fields. Posttreatment, this water can be reused by oil companies, in agriculture, or even as drinking water where needed. Globally, agriculture consumes about 70% of freshwater resources, making CETI's water remediation capabilities particularly valuable to local communities and Industries. ABOUT CYBER ENVIRO-TECH, INC. CETI is an international eco-conscious, oil/sludge, water and soil remediation Company. Using bi ...